Illuccix Prostate Cancer PSMA-PET Imaging Agent Approved in Finland
April 30, 2025
Telix Pharmaceuticals Limited announces that its prostate cancer PET imaging agent Illuccix has been granted marketing authorization by Fimea for the detection and localization of prostate-specific membrane
